Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation

By R. Cappato, H. Calkins, Shih‐Ann Chen, W. Davies, Y. Iesaka, J. Kalman, You-Ho Kim, G. Klein, A. Natale, D. Packer and 3 more. Circulation: Arrhythmia and Electrophysiology, 2005

2,489 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/0f401cf00ba248df583f0e27b3327a0d51a5726a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. M. Ezekowitz
2. Stanley Nattel
3. Gerhard Hindricks

Citations in the corpus

• 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation (2017, methodology): “It is difficult to directly compare adverse events from AF ablation to those from AADs.”
• Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation: The A4 Study (2008, neutral): “... 51.111.1 Episodes per month, median (IQR), n 13.5 (4.0–30.0) 12.0 (3.0–30.0) 12.0 (4.0–30.0) Duration of episodes, median (IQR), h 4.0 (1.0–12.0) 6.0 (2.0–15.0) 5.5 (1.0–12.0) Patients with 1 DC shock, n (%) 9 (17.0) 12 (20.3) 21 (18.8) Embolic events, n (%) 1 (1.9) 7 (11.9) 8 (7.1) Diabetes mel”
• 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “– 726,1039 In patients who experience symptomatic recurrences of AF despite antiarrhythmic drug therapy, all RCTs showed better sinus rhythm maintenance with catheter ablation than on antiarrhythmic drugs.(586,713,727,728) There is no current indication for catheter ablation to prevent cardiovascula”